PMID- 33612827 OWN - NLM STAT- MEDLINE DCOM- 20211027 LR - 20231107 IS - 1476-5462 (Electronic) IS - 0969-7128 (Print) IS - 0969-7128 (Linking) VI - 28 IP - 7-8 DP - 2021 Aug TI - Use of CRISPR/Cas9-mediated disruption of CNS cell type genes to profile transduction of AAV by neonatal intracerebroventricular delivery in mice. PG - 456-468 LID - 10.1038/s41434-021-00223-3 [doi] AB - Adeno-associated virus (AAV) transduction efficiency and tropism are conventionally determined by high expression of a fluorescent reporter gene. Emerging data has suggested that such conventional methods may underestimate AAV transduction for cells in which reporter expression from AAV vectors is undetectable. To explore an alternative method that captures AAV transduction in cells in which low expression of a cargo is sufficient for the intended activity, we sought after CRISPR/Cas9-mediated gene disruption. In this study, we use AAV to deliver CRISPR/guide RNA designed to abolish the genes NeuN, GFAP, or MOG expressed specifically in neurons, astrocytes, or oligodendrocytes respectively in the central nervous system (CNS) of mice. Abrogated expression of these cell-type-specific genes can be measured biochemically in CNS subregions and provides quantitative assessment of AAV transduction in these CNS cell types. By using this method, we compared CNS transduction of AAV9, AAV-PHP.B, and AAV-PHP.eB delivered via intracerebroventricular injection (ICV) in neonatal mice. We found both AAV-PHP.B and AAV-PHP.eB resulted in marked disruption of the NeuN gene by CRISPR/Cas9, significantly greater than AAV9 in several brain regions and spinal cord. In contrast, only modest disruption of the GFAP gene and the MOG gene was observed by all three AAV variants. Since the procedure of ICV circumvents the blood-brain barrier, our data suggests that, independent of their ability to cross the blood-brain barrier, AAV-PHP.B variants also exhibit remarkably improved neuronal transduction in the CNS. We anticipate this approach will facilitate profiling of AAV cellular tropism in murine CNS. CI - (c) 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature. FAU - Torregrosa, Tess AU - Torregrosa T AUID- ORCID: 0000-0001-9870-0993 AD - Biogen, Cambridge, MA, USA. FAU - Lehman, Sydney AU - Lehman S AD - Biogen, Cambridge, MA, USA. FAU - Hana, Sam AU - Hana S AD - Biogen, Cambridge, MA, USA. FAU - Marsh, Galina AU - Marsh G AD - Biogen, Cambridge, MA, USA. FAU - Xu, Shanqin AU - Xu S AD - Biogen, Cambridge, MA, USA. FAU - Koszka, Kathryn AU - Koszka K AD - Biogen, Cambridge, MA, USA. FAU - Mastrangelo, Nicole AU - Mastrangelo N AD - Biogen, Cambridge, MA, USA. FAU - McCampbell, Alexander AU - McCampbell A AD - Biogen, Cambridge, MA, USA. FAU - Henderson, Christopher E AU - Henderson CE AD - Biogen, Cambridge, MA, USA. FAU - Lo, Shih-Ching AU - Lo SC AUID- ORCID: 0000-0002-5187-0730 AD - Biogen, Cambridge, MA, USA. joyce.lo@biogen.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210222 PL - England TA - Gene Ther JT - Gene therapy JID - 9421525 SB - IM MH - Animals MH - CRISPR-Cas Systems MH - Central Nervous System MH - *Dependovirus/genetics MH - Gene Transfer Techniques MH - *Genetic Vectors/genetics MH - Mice MH - Neurons MH - Transduction, Genetic PMC - PMC8376643 COIS- The authors declare that they have no conflict of interest. EDAT- 2021/02/23 06:00 MHDA- 2021/10/28 06:00 PMCR- 2021/02/22 CRDT- 2021/02/22 05:50 PHST- 2020/07/03 00:00 [received] PHST- 2021/01/15 00:00 [accepted] PHST- 2020/12/01 00:00 [revised] PHST- 2021/02/23 06:00 [pubmed] PHST- 2021/10/28 06:00 [medline] PHST- 2021/02/22 05:50 [entrez] PHST- 2021/02/22 00:00 [pmc-release] AID - 10.1038/s41434-021-00223-3 [pii] AID - 223 [pii] AID - 10.1038/s41434-021-00223-3 [doi] PST - ppublish SO - Gene Ther. 2021 Aug;28(7-8):456-468. doi: 10.1038/s41434-021-00223-3. Epub 2021 Feb 22.